



Press Release

Cellzome and Santhera's business unit, Graffinity, awarded €2.2 million grant from German Government

Heidelberg, 12. October 2005 - Cellzome AG and Graffinity announced today that they will receive €2.2 million - €1.1 million each - from the German Ministry of Research and Education for the discovery of novel treatments for disorders of the immune system.

Cellzome and Graffinity will exploit their complementary technologies for the discovery of novel, selective small molecule leads, initially directed against several kinases in signalling pathways of the immune system. Over the course of the next two years, Graffinity will screen up to nine Cellzome targets using its unique fragment-based screening platform. Cellzome will apply its proteomics platform both for the identification of targets and the selectivity profiling of hits and leads arising from the collaboration.

"We are looking forward to working with Cellzome on this exciting multi-target project. The grant funding gives us the right means to collaborate on a broader basis and to demonstrate Graffinity's sophisticated screening capabilities with target-rich companies. In addition, we will use the funding to further increase the sensitivity of our screening technology," said Kristina Schmidt, Managing Director of Graffinity.

Tim Edwards, CEO of Cellzome, added, "We are pleased that the combination of Cellzome's and Graffinity's technologies has been recognised by the German government which has chosen to provide significant support for this promising project. This is another validation of Cellzome's approach to drug discovery, and we look forward to working with Graffinity's novel fragment-based approach to progress interesting targets in inflammatory pathways."

About Cellzome Inc.

Cellzome is a drug discovery company with world-class, proprietary proteomics technology for target and lead identification, and a drug discovery programme in Alzheimer's disease. The technology provides molecular understanding of disease and helps to identify the role of active compounds and their possible side effects, and thus provides insight into how potential drugs might behave in man.

Cellzome's strategy is to commercialise its technology through building its own pipeline of clinical products and through collaboration with leading pharmaceutical partners. To date it has signed such collaborations with Bayer HealthCare, Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a large pan-therapeutic collaboration with Novartis and, in March 2005, a drug discovery collaboration in Alzheimer's disease with Ortho-McNeil Pharmaceutical and J&JPRD.

Cellzome's holding company is domiciled in the US and employs about 75 people across its two operating subsidiaries in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: www.cellzome.com

About Graffinity

Graffinity is a business unit of Santhera Pharmaceuticals AG. Graffinity is the premier partner for fragment-based drug discovery of small molecule pharmaceuticals. The unique approach includes chemical fragment microarrays, label-free imaging of protein-ligand interactions, computational chemistry and lead discovery. The technology platform offers a new drug discovery paradigm for the rapid conversion of genomic information into novel, high quality leads and drug candidates. Graffinity applies this technology in established high-profile collaborations with leading Pharma- and Biotech companies. For more information about Graffinity, please visit our website: www.graffinity.com. For further information regarding Santhera, please visit the website: www.santhera.com

For further information please contact:

Cellzome AG
Tim Edwards, CEO
Tel: +49 (0) 6221-137 57-100
press@cellzome.com

Media Contact
Hogarth Partnership
John Olsen/Melanie Toyne-Sewell
Tel: +44 (0) 207 357 9477
mtoyne-sewell@hogarthpr.co.uk

Graffinity
Business Unit of Santhera AG
Dr. Kristina Schmidt, General Manager
Tel: +49 (0) 6221-6510-0
kristina.schmidt@graffinity.com

Santhera Pharmaceuticals AG
Dr. Klaus Schollmeier, CEO
Tel: +41 (0) 61 906 8952
klaus.schollmeier@santhera.com